medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2004, Number 5

Next >>

Salud Mental 2004; 27 (5)

The concept of melancholia and antidepressant treatment

Kragh-Sørensen P, Bjerregaard SK

Language: English
References: 35
Page: 1-7
PDF size: 71.67 Kb.


Text Extraction

Why have we on this occasion chosen this particular topic? At first glance it does not seem too interesting, as among psychiatrists, clinical psychopharmacologists and other highly ranged scientists who work with molecular biology, there appears to be a firm conviction that the introduction of DSM-III (1) in 1980 presented a major innovation in clinical psychiatry, which put an end to the insecurity and disagreement found before 1980 regarding the diagnostics and classifications of depressive disorders.
It is correct that the introduction of DSM-III was a paradigmatic change from nosological to syndromatical diagnostics and classifications. It is also correct that the previous classifications of depressive disorders were based on prototypical descriptions of the illness with unknown, but presumed aetiologies, with ill-defined boundaries and low reliability, which was suggested to impede the quality of research and of clinical psychiatry (2). In this context, DSM-III introduced a purely descriptive non-aetiological classification with operationally defined categories based on diagnostic criteria with proven high reliability.



REFERENCES

  1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition (DSMIII). Washington, 1980.

  2. BERTELSEN A: Reflections on the clinical utility of the ICD-10 and DSM-IV classifications and their diagnostic criteria. Australian New Zealand J Psychiatry, 33:166-173, 1999.

  3. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. 4th edition (DSM-IV). Washington, 1994.

  4. WORLD HEALTH ORGANIZATION: The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research, Geneva, 1993.

  5. KRAEPELIN E: Psychiatrie. Ein Lehrbuch Für Studierende und Ärzte. 6. ed. Verlag von Johann Ambrosius Barth, Leipzig, 1899.

  6. HEALY D: The Antidepressant Era. Harvard University Press. Cambridge and London, 1997.

  7. BALDWIN D, THOMSON C: The future of antidepressant pharmacotherapy. World Psychiatry, 2(1):3-8, 2003.

  8. KIRSCH I, MOORE TJ, SCOBORIA A, NICHOLLS SS: The Emperor’s new drugs: an analysis of antidepressant medication data submitted to the US food and drug administration. Prevention Treatment, 5(23), July 15, 2002.

  9. KIRSCH I, SAPIRSTEIN G: Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication. Prevention Treatment, 1(0002a):1-13, June 26, 1998.

  10. MONCRIEFF J: The antidepressant debate. Editorial. British J Psychiatry, 180: 193-194, 2002.

  11. PARKER G: (Editorial) ‘New’ and ‘old’ antidepressants: all equal in the eyes of the lore? British J Psychiatry, 179:95-96, 2001.

  12. THASE ME: Antidepressant effects: The suit may be small, but the fabric is real. Prevention Treatment, 5(32), July 15, 2002.

  13. WALSH BT, SEIDMAN SN, SYSKO R, GOULD M: Placebo response in studies of major depression. Variable, substantial, and growing. JAMA, 287(14): 1840-1847, 2002.

  14. ZIMMERMAN M, MATTIA JI, POSTERNAK MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice. Am J Psychiatry, 159:469-473, 2002.

  15. AMERICAN PSYCHIATRIC ASSOCIATION: Practice guidelines for the treatment of psychiatric disorders. Compendium, 507-508, 528, 2002.

  16. VETTER PH, VON PRITZBUER J, JUNGMANN K, KROPP P, KOLLER O: The validity of the ICD-10 classification of recurrent affective disorders: do endogenous and psychogenic depressions form a homogeneous diagnostic group? Psychopathology; 34 (1):36-42, 2001

  17. HILDEBRANDT MG, STEYERBERG EW, STAGE KB, PASSCHIER J, KRAGH-SØRENSEN P, DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Are gender differences important for the Clinical Effects of Antidepressants? Am J Psychiatry, 160:1643-1650, 2003.

  18. THIELE J, HOLZINGER O: “Ueber o-diaminodibenzyl”. Annales Chemische Liebiegs, 305:96-102, 1899.

  19. AYD FJ: Amitriptyline (elavil) therapy for depressive reactions. Psychosomatics, 1:320-325, 1960.

  20. AYD FJ: Recognizing the Depressed Patient. Grune and Stratton, New York, 1961.

  21. HAMILTON ME: A Rating scale for Depression. J Neurology Neurosurgery Psychiatry, 23:56-62, 1960.

  22. ROTH M, GURNEY C, MOUNTJOY CQ: The newcastle rating scales. Acta Psychiatr Scand (Suppl), 310:42-54, 1983.

  23. KRAGH-SØRENSEN P: Monitoring plasma concentration of nortriptyline. Methodological, pharmacokinetic and clinical aspects. Dan Med Bull, 1985 (Thesis) 32 (1):29-53, 1984.

  24. HAMMER W, SJÖQVIST F: Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci, 6:1895-1903, 1967.

  25. ALEXANDERSON B: On Interindividual Variability in Plasma Levels of Nortriptyline and Desmethylimipramine in Man: A Pharmacokinetic and Genetic Study. Linköping University Medical Dissertations, 6:1-46, 1972a;.

  26. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Clomipramine Dose-effect Study in Patients with Depression: Clinical end Points and Pharmacokinetics. Clin Pharmacol Ther, 66:152-65, 1999.

  27. KRAGH-SØRENSEN P, HANSEN CE, ÅSBERG M: Plasma levels of nortriptyline in the treatment of endogenous depression. Acta Psychiatr Scand, 49:444-56, 1973.

  28. KRAGH-SØRENSEN P, HANSEN CE, BAASTRUP PC, HVIDBERG EF: Self-inhibiting action of nortriptyline’s antidepressive effect at high plasma levels. A randomized, double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia (Berl.), 45:305-12, 1976.

  29. BURROWS GD, BRUCE A, SCOGGINS BT, TURECEK LR, DAVIES B: Plasma nortriptyline and clinical response. Clin Pharmacol Ther, 16(4):639-44, 1974a.

  30. DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 90:131-138, 1986.

  31. DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorders, 18:289-299, 1990.

  32. STAGE KB, BECH P, GRAM LF, KRAGH-SØRENSEN P, ROSENBERG C, OHRBERG S: Are inpatients depressives more often of the melancholic subtype? Danish University Antidepressant Group. Acta Psychiatr Scand, 98(6):432-436, 1998.

  33. HAMILTON M: Development of a rating scale for primary depressive illness. British J Social Clinical Psychology, 6:278- 296, 1967.

  34. GUERNEY C: Diagnostic Scales for Affective Disorders. Proc 5th World Conference of Psychiatry, 130, Mexico City, 1971.

  35. STAGE KB, KRAGH-SØRENSEN P: Data to be published.




2020     |     www.medigraphic.com